(Total Views: 461)
Posted On: 05/19/2025 12:21:27 PM
Post# of 153344
Quote:
Yes, the FDA has accepted PD-L1 as a biomarker for breast cancer, specifically in the context of triple-negative breast cancer (TNBC).
They are using PD-L1 to select patients for a trial, not as an endpoint. This is analogous to our trials requiring CCR5+ expression in patients.
(9)
(0)Scroll down for more posts ▼
